Search Results - Jonathan A. Fallowfield

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    Misclassification of coffee consumption data and the development of a standardised coffee unit measure

    Misclassification of coffee consumption data and the development of a standardised coffee unit measure by Paul Roderick, Sean Ewings, Robin Poole, Julie Parkes, Jonathan A Fallowfield

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease

    A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease by Maria Jimenez Ramos, Timothy J. Kendall, Ignat Drozdov, Jonathan A. Fallowfield

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records

    Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records by Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study

    All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study by Oliver J. Kennedy, Jonathan A. Fallowfield, Robin Poole, Peter C. Hayes, Julie Parkes, Paul J. Roderick

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Reliable computational quantification of liver fibrosis is compromised by inherent staining variation

    Reliable computational quantification of liver fibrosis is compromised by inherent staining variation by Stuart Astbury, Jane I Grove, David A Dorward, Indra N Guha, Jonathan A Fallowfield, Timothy J Kendall

    Published 2021-09-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)

    A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP) by Fiona J. Gifford, Philip D. J. Dunne, Graeme Weir, Hamish Ireland, Catriona Graham, Sharon Tuck, Peter C. Hayes, Jonathan A. Fallowfield

    Published 2020-03-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease

    Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease by Rohit Sinha, Khalida A. Lockman, Natalie Z.M. Homer, Edward Bower, Paul Brinkman, Hugo H. Knobel, Jonathan A. Fallowfield, Alan J. Jaap, Peter C. Hayes, John N. Plevris

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis

    Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis by Andrea Dennis, Matt D. Kelly, Carolina Fernandes, Sofia Mouchti, Jonathan A. Fallowfield, Gideon Hirschfield, Michael Pavlides, Michael Pavlides, Michael Pavlides, Stephen Harrison, Stephen Harrison, Manu V. Chakravarthy, Rajarshi Banerjee, Arun Sanyal

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Study protocol: HepaT1ca – an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies

    Study protocol: HepaT1ca – an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies by Damian J. Mole, Jonathan A. Fallowfield, Timothy J. Kendall, Fenella Welsh, Scott I. Semple, Velicia Bachtiar, Matt Kelly, Stephen J. Wigmore, O. James Garden, Henry R. Wilman, Rajarshi Banerjee, Myrddin Rees, Michael Brady

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility study

    Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility study by Anna M. Hoy, Natasha McDonald, Ross J. Lennen, Matteo Milanesi, Amy H. Herlihy, Timothy J. Kendall, William Mungall, Michael Gyngell, Rajarshi Banerjee, Robert L. Janiczek, Philip S. Murphy, Maurits A. Jansen, Jonathan A. Fallowfield

    Published 2018-07-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Addition of hyaluronic acid to the FIB‐4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study

    Addition of hyaluronic acid to the FIB‐4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabet... by Sheila M. Grecian, Stela McLachlan, Jonathan A. Fallowfield, Peter C. Hayes, Indra Neil Guha, Joanne R. Morling, Stephen Glancy, Rachel M. Williamson, Rebecca M. Reynolds, Brian M. Frier, Nicola N. Zammitt, Jackie F. Price, Mark W. J. Strachan

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer.

    Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. by Damian J Mole, Jonathan A Fallowfield, Ahmed E Sherif, Timothy Kendall, Scott Semple, Matt Kelly, Gerard Ridgway, John J Connell, John McGonigle, Rajarshi Banerjee, J Michael Brady, Xiaozhong Zheng, Michael Hughes, Lucile Neyton, Joanne McClintock, Garry Tucker, Hilary Nailon, Dilip Patel, Anthony Wackett, Michelle Steven, Fenella Welsh, Myrddin Rees, HepaT1ca Study Group

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Genome‐Wide Association Study of NAFLD Using Electronic Health Records

    Genome‐Wide Association Study of NAFLD Using Electronic Health Records by Cameron J. Fairfield, Thomas M. Drake, Riinu Pius, Andrew D. Bretherick, Archie Campbell, David W. Clark, Jonathan A. Fallowfield, Caroline Hayward, Neil C. Henderson, Peter K. Joshi, Nicholas L. Mills, David J. Porteous, Prakash Ramachandran, Robert K. Semple, Catherine A. Shaw, Cathie L.M. Sudlow, Paul R.H.J. Timmers, James F. Wilson, Stephen J. Wigmore, Ewen M. Harrison, Athina Spiliopoulou

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

    Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. by Victoria K Snowdon, Neil J Lachlan, Anna M Hoy, Patrick W F Hadoke, Scott I Semple, Dilip Patel, Will Mungall, Timothy J Kendall, Adrian Thomson, Ross J Lennen, Maurits A Jansen, Carmel M Moran, Antonella Pellicoro, Prakash Ramachandran, Isaac Shaw, Rebecca L Aucott, Thomas Severin, Rajnish Saini, Judy Pak, Denise Yates, Neelesh Dongre, Jeremy S Duffield, David J Webb, John P Iredale, Peter C Hayes, Jonathan A Fallowfield

    Published 2017-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: